Schizophrenia Therapeutics Market - Global Forecast 2026-2032

The schizophrenia therapeutics market is evolving rapidly, as scientific breakthroughs, care model innovation, and shifting commercial frameworks converge to create new opportunities and challenges for senior leaders.

Market Snapshot: Schizophrenia Therapeutics Market

The global schizophrenia therapeutics market expanded from USD 6.21 billion in 2025 to USD 6.54 billion in 2026. With a projected compound annual growth rate (CAGR) of 6.47%, the market is anticipated to reach USD 9.64 billion by 2032. This expansion is propelled by continuous pharmaceutical innovation, the integration of advanced delivery systems, and a strategic emphasis on comprehensive, patient-centered care solutions.

Scope & Segmentation

Therapeutic Modalities: Includes non-pharmacological therapies (such as cognitive-behavioral therapy, electroconvulsive therapy, and family therapy) and pharmacological therapies (such as injectable medications and oral medications focused on symptom management and relapse prevention).
Therapeutic Classes: Covers first-generation antipsychotics, second-generation antipsychotics, mood stabilizers, and selective serotonin reuptake inhibitors, with special emphasis on the adjunctive roles these play in complex cases.
Mechanistic Pathways: Differentiates between dopamine receptor antagonists, glutamate modulators, and serotonin dopamine activity modulators as key biological approaches targeting varied symptom clusters.
Formulation Types: Examines formulations such as inserts and patches, liquid solutions, and solid tablets, each selected to optimize dosing flexibility, adherence, and patient preference.
End Users: Assesses dynamics for homecare settings, hospitals, mental health clinics, and research institutes, each presenting unique administration, procurement, and reimbursement challenges.
Patient Settings: Focuses on inpatient versus outpatient care and the resulting impact on treatment continuity and resource use.
Patient Demographics: Segments include adult, geriatric, and pediatric patient groups, each with distinct comorbidity profiles, service needs, and tolerability considerations.
Geographic Regions: Analysis spans the Americas, Europe, Middle East & Africa, and Asia-Pacific, capturing variances in payer systems, regulatory landscapes, and care infrastructure.

Key Takeaways: Strategic Insights for Senior Leaders

Schizophrenia therapeutics are at a turning point as pharmacological advances, sustained-release formulations, and integrated psychosocial interventions drive a comprehensive approach to patient care.
The clinical focus is shifting beyond symptom reduction to address functional recovery, cognitive health, and long-term adherence—factors that influence payer decisions and care delivery models.
Segmented approaches in mechanism, formulation, and care setting are critical to defining value pathways and aligning product development with payer and provider needs.
Regional differences in regulatory standards and reimbursement strategies require tailored commercialization tactics to optimize adoption and market penetration.
Manufacturers and stakeholders must strengthen supply chain agility and build resilient sourcing models, responding proactively to regulatory and geopolitical pressures.
Partnerships among industry, academia, and care providers are essential to accelerate evidence generation and ensure therapies are positioned within holistic service models.

Tariff Impact: Navigating Supply Chain and Access Dynamics

Recent adjustments in tariffs have altered pharmaceutical supply chains, prompting companies to reconsider sourcing, inventory management, and regional production strategies. These changes have heightened the importance of dual-sourcing, local partnerships, and regulatory compliance to safeguard product availability and support seamless patient access. Procurement operations now weigh cost, quality, and timeline variables to manage risk, while payers are requesting transparent documentation to assess the holistic cost implications of tariff-related expense shifts.

Methodology & Data Sources

This report utilizes a mixed-methods approach, gathering qualitative insights through primary expert interviews with clinicians, payers, and service providers, supported by a systematic review of peer-reviewed literature, regulatory documents, and clinical trial data. Secondary analysis draws from company disclosures and technology trend reports for a multi-angle validation of market trends and evidence gaps.

Schizophrenia Therapeutics Market: Why This Report Matters

Enables senior executives to align R&D and commercial strategies with evolving evidence, supply chain challenges, and payer priorities.
Provides actionable guidance for maintaining market access amid policy shifts and regional care model differences.
Supports informed investment, partnership, and product development decisions through comprehensive segmentation and cross-regional analysis.

Conclusion

As scientific and operational dynamics converge, tailored, evidence-based strategies and ecosystem partnerships are critical to successful market engagement in schizophrenia therapeutics. Adaptability and patient focus remain central for translating innovation into real-world impact.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Schizophrenia Therapeutics Market, by Type

8.1. Non-Pharmacological Therapies
8.1.1. Cognitive-Behavioral Therapy (CBT)
8.1.2. Electroconvulsive Therapy (ECT)
8.1.3. Family Therapy
8.2. Pharmacological Therapies
8.2.1. Injectable Medications
8.2.2. Oral Medications

9. Schizophrenia Therapeutics Market, by Therapeutic Class

9.1. Antipsychotics
9.1.1. First-Generation Antipsychotics
9.1.2. Second-Generation Antipsychotics
9.2. Mood Stabilizers
9.3. Selective Serotonin Reuptake Inhibitors

10. Schizophrenia Therapeutics Market, by Mechanism of Action

10.1. Dopamine Receptor Antagonists
10.2. Glutamate Modulators
10.3. Serotonin Dopamine Activity Modulators

11. Schizophrenia Therapeutics Market, by Formulation Type

11.1. Inserts and Patches
11.2. Liquid Solutions
11.3. Solid Tablets

12. Schizophrenia Therapeutics Market, by End Users

12.1. Homecare Settings
12.2. Hospitals
12.3. Mental Health Clinics
12.4. Research Institutes

13. Schizophrenia Therapeutics Market, by Patient Settings

13.1. Inpatient Care
13.2. Outpatient Care

14. Schizophrenia Therapeutics Market, by Patient Demographics

14.1. Adult Patients
14.2. Geriatric Patients
14.3. Pediatric Patients

15. Schizophrenia Therapeutics Market, by Region

15.1. Americas
15.1.1. North America
15.1.2. Latin America
15.2. Europe, Middle East & Africa
15.2.1. Europe
15.2.2. Middle East
15.2.3. Africa
15.3. Asia-Pacific

16. Schizophrenia Therapeutics Market, by Group

16.1. ASEAN
16.2. GCC
16.3. European Union
16.4. BRICS
16.5. G7
16.6. NATO

17. Schizophrenia Therapeutics Market, by Country

17.1. United States
17.2. Canada
17.3. Mexico
17.4. Brazil
17.5. United Kingdom
17.6. Germany
17.7. France
17.8. Russia
17.9. Italy
17.10. Spain
17.11. China
17.12. India
17.13. Japan
17.14. Australia
17.15. South Korea

18. United States Schizophrenia Therapeutics Market
19. China Schizophrenia Therapeutics Market

20. Competitive Landscape

20.1. Market Concentration Analysis, 2025
20.1.1. Concentration Ratio (CR)
20.1.2. Herfindahl Hirschman Index (HHI)
20.2. Recent Developments & Impact Analysis, 2025
20.3. Product Portfolio Analysis, 2025
20.4. Benchmarking Analysis, 2025
20.5. AbbVie Inc.
20.6. Acadia Pharmaceuticals Inc.
20.7. Alkermes Plc
20.8. Amneal Pharmaceuticals, LLC
20.9. Astellas Pharma Inc.
20.10. AstraZeneca plc
20.11. BioXcel Therapeutics, Inc.
20.12. Boehringer Ingelheim International GmbH
20.13. Bristol Myers Squibb Company
20.14. Cipla Limited
20.15. Delpor, Inc.
20.16. Dr. Reddy’s Laboratories Ltd.
20.17. Eli Lilly and Company
20.18. Gedeon Richter Plc
20.19. GlaxoSmithKline plc.
20.20. Glenmark Pharmaceuticals Limited
20.21. Johnson & Johnson Services, Inc.
20.22. Lundbeck A/S
20.23. Lupin Limited
20.24. Luye Pharma Group Ltd
20.25. Lyndra Therapeutics Inc
20.26. Meiji Holdings Co., Ltd.
20.27. Merck & Co., Inc.
20.28. Neurocrine Biosciences, Inc.
20.29. Novartis AG
20.30. Otsuka Holdings Co., Ltd.
20.31. Pfizer Inc.
20.32. Reviva Pharmaceuticals Holdings, Inc.
20.33. Sanofi S.A
20.34. Sumitomo Pharma Co., Ltd.
20.35. Sun Pharmaceutical Industries Limited
20.36. Takeda Pharmaceutical Company Limited
20.37. Teva Pharmaceutical Industries Ltd.
20.38. Torrent Pharmaceuticals Ltd.
20.39. Vanda Pharmaceuticals Inc.

List of Figures

FIGURE 1. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 15. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COGNITIVE-BEHAVIORAL THERAPY (CBT), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ELECTROCONVULSIVE THERAPY (ECT), BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FAMILY THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FIRST-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SECOND-GENERATION ANTIPSYCHOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MOOD STABILIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY DOPAMINE RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GLUTAMATE MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SEROTONIN DOPAMINE ACTIVITY MODULATORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INSERTS AND PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY LIQUID SOLUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SOLID TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MENTAL HEALTH CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY INPATIENT CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY OUTPATIENT CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 95. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 96. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 97. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 98. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 105. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 107. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 108. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 116. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 117. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 118. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 138. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 140. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 141. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 142. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 143. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 144. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 145. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 146. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 147. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 148. EUROPE SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 159. MIDDLE EAST SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 160. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 161. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 162. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 163. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 164. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 165. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 166. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 167. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 168. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 169. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 170. AFRICA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 179. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 180. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 181. ASIA-PACIFIC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 182. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 183. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 185. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 186. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 187. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 188. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 189. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 190. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 191. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 192. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 193. ASEAN SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 194. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 195. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 196. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 197. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 198. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 199. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 200. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 201. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 202. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 203. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 204. GCC SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 216. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 217. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 218. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 219. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 220. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 221. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 222. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 223. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 224. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 225. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 226. BRICS SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 227. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 228. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 229. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 230. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 231. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 232. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 233. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 234. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 235. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 236. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 237. G7 SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 238. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 239. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 240. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 241. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 242. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 243. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 244. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 245. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 246. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 247. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 248. NATO SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 249. GLOBAL SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 251. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 252. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 253. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 254. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 255. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 256. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 257. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 258. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 259. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 260. UNITED STATES SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
TABLE 261. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 262. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
TABLE 263. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY NON-PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 264. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PHARMACOLOGICAL THERAPIES, 2018-2032 (USD MILLION)
TABLE 265. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
TABLE 266. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY ANTIPSYCHOTICS, 2018-2032 (USD MILLION)
TABLE 267. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
TABLE 268. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY FORMULATION TYPE, 2018-2032 (USD MILLION)
TABLE 269. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
TABLE 270. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT SETTINGS, 2018-2032 (USD MILLION)
TABLE 271. CHINA SCHIZOPHRENIA THERAPEUTICS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Schizophrenia Therapeutics market report include:

AbbVie Inc.
Acadia Pharmaceuticals Inc.
Alkermes Plc
Amneal Pharmaceuticals, LLC
Astellas Pharma Inc.
AstraZeneca plc
BioXcel Therapeutics, Inc.
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Company
Cipla Limited
Delpor, Inc.
Dr. Reddy’s Laboratories Ltd.
Eli Lilly and Company
Gedeon Richter Plc
GlaxoSmithKline plc.
Glenmark Pharmaceuticals Limited
Johnson & Johnson Services, Inc.
Lundbeck A/S
Lupin Limited
Luye Pharma Group Ltd
Lyndra Therapeutics Inc
Meiji Holdings Co., Ltd.
Merck & Co., Inc.
Neurocrine Biosciences, Inc.
Novartis AG
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Reviva Pharmaceuticals Holdings, Inc.
Sanofi S.A
Sumitomo Pharma Co., Ltd.
Sun Pharmaceutical Industries Limited
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
Torrent Pharmaceuticals Ltd.
Vanda Pharmaceuticals Inc.

Table Information

Report Attribute	Details
No. of Pages	191
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 6.54 Billion
Forecasted Market Value ( USD ) by 2032	$ 9.64 Billion
Compound Annual Growth Rate	6.4%
Regions Covered	Global
No. of Companies Mentioned	36

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3511EUR$3,939USD£3,045GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3787EUR$4,249USD£3,285GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5133EUR$5,759USD£4,452GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6212EUR$6,969USD£5,387GBP

Market Snapshot: Schizophrenia Therapeutics Market

Scope & Segmentation

Key Takeaways: Strategic Insights for Senior Leaders

Tariff Impact: Navigating Supply Chain and Access Dynamics

Methodology & Data Sources

Schizophrenia Therapeutics Market: Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Schizophrenia Drugs Market - A Global and Regional Analysis: Focus on Country and Regional Analysis - Analysis and Forecast, 2025-2035

Schizophrenia Therapeutics - Global Strategic Business Report

Schizophrenia- Pipeline Insight, 2025

Antipsychotic Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Product Type

Schizophrenia Drugs Market Report 2025